[
  {
    "section": "section:1",
    "title": "Figitumumab..."
  },
  {
    "section": "section:2",
    "title": "Abstract"
  },
  {
    "section": "section:2",
    "title": "Introduction"
  },
  {
    "section": "section:2",
    "title": "Materials and methods"
  },
  {
    "section": "section:3",
    "title": "Study population"
  },
  {
    "section": "section:3",
    "title": "Study design and dosing"
  },
  {
    "section": "section:3",
    "title": "Assessments and analyses"
  },
  {
    "section": "section:2",
    "title": "Results"
  },
  {
    "section": "section:3",
    "title": "Baseline characteristics"
  },
  {
    "section": "section:3",
    "title": "Safety and tolerability"
  },
  {
    "section": "section:3",
    "title": "Pharmacokinetics"
  },
  {
    "section": "section:3",
    "title": "Biomarkers"
  },
  {
    "section": "section:3",
    "title": "Antitumor activity"
  },
  {
    "section": "section:3",
    "title": "Relationship between antitumor activity and biomarkers"
  },
  {
    "section": "section:2",
    "title": "Discussion"
  },
  {
    "section": "section:2",
    "title": "References"
  }
]